Ianalumab

• A phase 2 study of ianalumab in adults with primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who … Pending
  2024-518231-11-00 Phase II 9 countries Novartis Pharma AG
• A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj… Recruiting
  2023-508996-35-00 Phase II 7 countries Novartis Pharma AG
• A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting
  2024-510635-21-00 Phase III 6 countries Novartis Pharma AG
• An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan… Recruiting
  2024-515280-60-00 Phase III 5 countries Novartis Pharma AG
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting
  2023-505929-14-00 Phase III 11 countries Novartis Pharma AG
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended
  2024-511933-36-00 Phase II 10 countries Novartis Pharma AG
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended
  2022-502966-26-01 Phase III 16 countries Novartis Pharma AG
• Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended
  2023-508499-12-00 Phase III 4 countries Novartis Pharma AG
• A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen… Ended
  2024-512890-28-00 Phase III 11 countries Novartis Pharma AG
• Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended
  2023-508498-97-00 Phase III 7 countries Novartis Pharma AG
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended
  2024-511068-10-00 Phase III 11 countries Novartis Pharma AG
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended
  2023-508559-37-00 Phase III 9 countries Novartis Pharma AG
• Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended
  2024-511069-12-00 Phase III 9 countries Novartis Pharma AG
• Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships with Clinical Assessments Ended
  2023-508957-24-00 Phase II 1 country Novartis Pharma AG
• A study to assess different investigational drugs for the treatment if hidradenitis suppurativa Ended
  2023-509296-16-00 Phase II 6 countries Novartis Pharma AG
• A clinical trial to find out if VAY736 can help people with autoimmune hepatitis, a disease where your immune system attacks your own liver Ended
  2023-508859-39-00 Phase II/III 2 countries Novartis Pharma AG

Showing 1–16 of 16 trials